Comparative Pharmacology
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus CROMOPTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus CROMOPTIC.
ACUVUE THERAVISION WITH KETOTIFEN vs CROMOPTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
Mast cell stabilizer that inhibits the release of histamine and other inflammatory mediators from mast cells. Also inhibits eosinophil chemotaxis and activation.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
1-2 drops in each eye 4 times daily for conjunctivitis; 1 drop in each eye 2-4 times daily for allergic conjunctivitis prophylaxis.
None Documented
None Documented
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
1.3 hours (terminal elimination half-life); clinically, due to rapid elimination, dosing is required 4 times daily for sustained effect.
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Primarily renal excretion of unchanged drug (approximately 70% within 24 hours); the remainder is excreted in feces via biliary elimination (approximately 30%).
Category A/B
Category C
Antihistamine / Mast Cell Stabilizer
Mast Cell Stabilizer